Unity Biotechnology, Inc. Operating Lease, Impairment Loss
Unity Biotechnology, Inc. reported Operating Lease, Impairment Loss of $1.90 million for the 12-month period ending 2024-12-31, per its 10-Q filed 2025-04-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2025-04-22
- Unity Biotechnology, Inc. operating lease, impairment loss for the quarter ending 2023-12-31 was $0.00.
- Unity Biotechnology, Inc. operating lease, impairment loss for the quarter ending 2023-09-30 was $4.00M.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.90M 10-Q · filed 2025-04-22 | |||
| 2023-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2025-04-22 | $4.00M derived: sum of 2 quarters · filed 2025-04-22 | $4.00M 10-Q · filed 2025-04-22 | |
| 2023-09-30 | $4.00M 10-Q · filed 2023-11-13 | $4.00M 10-Q · filed 2023-11-13 |